Home / News

News

New to The Street TV Re-signs PetVivo Holdings, Inc. (PETV) for 12 Part Series Including Additional Syndicated Network TV Broadcasts, Commercials and Digital Billboards

New to The Street TV Re-signs PetVivo Holdings, Inc. (PETV) for 12 Part Series Including Additional Syndicated Network TV Broadcasts, Commercials and Digital Billboards
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- FMW Media Works, Inc’s New to The Street TV show announces its newest contract with PetVivo Holdings, Inc. (NASDAQ:PETV) in the production, broadcasting and distribution of TV commercials and digital billboards with a start date, September 21, 2021.

The agreement calls for 600 TV commercials, 50 commercials per month at 30 second televised spot airings over the next 6-months on Fox News, Fox Business Network, Bloomberg Television, CNBC, Newsmax TV, CNN, and MSNBC. The digital billboard media advertisements to run in lower Manhattan, New York City, NY with a minimum of 2,400 ads per day.

Currently, Mr. John Lai, Chief Executive Officer (CEO) at PetVivo Holdings, Inc. continues to be interviewed about PETV’s corporate on-goings on New to The Street TV’s long-form syndicated airings; interviews to continue with the added commercial / billboard support per the agreement.

Mr. John Lai, CEO, PetVivo Holdings, Inc. states, “These commercials and digital billboards are designed to inform the public on our Company’s Spryng™ with OsteoCushion™ Technology which is a one-time treatment delivered by your pet’s veterinarian as an intra-articular injection that treats osteoarthritis and is designed to help reinforce the articulating cartilage barrier between the bones to protect the remaining cartilage and bone to improve joint function. We are confident that the upcoming PETV ad campaigns can inform the public on the Company’s mission in helping pet owners with the well-being of their pets and in promoting the arsenal of other PETV products being developed for the treatment of both animals and people. Working with New to the Street and their sophisticated media production staff and writers, together we developed a fantastic media platform to get our Corporate message and mission out about PETV.”

Mr. Vincent Caruso, CEO FMW Media Corp. and the Creator / Producer of New to The Street TV states, “New to the Street TV and its staff of dedicated professional looks forward in the production and distribution of both the commercial and billboard airings, content designed to inform the public on the veterinarian products sold and developed at PetVivo Holdings, Inc. The campaign provides a platform for the public to become aware of the pet health products and treatments available from PETV.”

Management at PetVivo Holdings, Inc. believes the commercial airings and billboard streaming can provide an effective information medium about the Company’s products, and can inform both current and potential investors about the Company’s on-going growth of its operations.

About PetVivo Holdings, Inc. (NASDAQ:PETV):

PetVivo, Inc. (NASDAQ:PETV) is based in Minneapolis, Minnesota. It is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. PetVivo believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals - https://petvivo.com/.

About FMW Media:

FMW Media operates one of the longest-running U.S. and International sponsored and Syndicated Nielsen Rated programming TV brands "New to the Street," and its blockchain show "Exploring The Block." Since 2009, these brands run biographical interview segment shows across major U.S. Television networks. The TV platforms reach over 540 million homes both in the US and international markets. FMW recently added Newsmax to its broadcasting platform with its first show broadcasted Sunday, December 27th. The NEWSMAX- “New to The Street” show is syndicated on Sundays at 10-11 AM ET, and broadcasted on Fox Business Network, Mondays and Tuesdays at 10:30 PM PT. FMW is also one of the nation's largest buyers of linear Television long and short form- https://www.newsmaxtv.com/Shows/New-to-the-Street and https://www.newtothestreet.com/

Safe Harbor Statement:

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.

FMW Media Contact:
Bryan Johnson
+1 (631) 766-7462
Bryan@NewToTheStreet.com

And

“New to The Street” Business Development office
Support@NewtoTheStreet.com
1-516-696-5900

Josh Wilhelm Joins PetVivo Holdings, Inc. as the Director of Manufacturing

Josh Wilhelm Joins PetVivo Holdings, Inc. as the Director of Manufacturing

MINNEAPOLIS, MN, US, Sept. 08, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Josh Wilhelm has accepted a position with the Company as its new Director of Manufacturing.

"We are incredibly fortunate to have secured a manufacturing professional such as Josh who possesses expertise in cGMP manufacturing, process engineering, and quality systems,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Josh is an experienced professional in assembling, coordinating and training manufacturing teams, and has already brought to PetVivo two experienced manufacturing veterans that are currently working with Josh to produce our ground-breaking product, spryng for commercial sale."

Josh Wilhelm

Mr. Wilhelm was the Director of Islet Manufacturing and R&D at the Schulze Diabetes Institute (“SDI”), coordinating the islet isolation and research activities of the "Isolation Core". As the Director of Manufacturing at SDI, Mr. Wilhelm supervised all cGMP manufacturing, process engineering, and quality systems. He further assumed the role at SDI of lead supervisor for human clinical islet manufacturing, managed both clinical and pre-clinical activities of the team and pursued research related to understanding and improving islet isolation yields and islet graft function. Mr. Wilhelm obtained his M.S. in Biomedical Engineering from the University of Minnesota in 2004 and entered industry to explore the real-world application of biomaterials and cell, tissue, and gene therapies for Medtronic, Inc and several local medical device and biotechnology start-ups.

“I am elated at the prospects of leading the manufacturing team of PetVivo, a company whose technology has a multitude of applications that enhance the lives of dogs and horses, as well as humans,” said Mr. Wilhelm. “In the last year, our team of scientists and engineers have organized an extremely safe and efficient system to produce spryng, our therapeutic product for the treatment of arthritis in companion animals. I am looking forward to assisting the Company in meeting the demand for this life-changing product to help animals suffering from osteoarthritis.”

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

 

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com 
(952) 405-6216

 

Forward-Looking commercial Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

 

Mark Middleton Joins PetVivo Holdings, Inc. as the National Director of Sales

Mark Middleton Joins PetVivo Holdings, Inc. as the National Director of Sales

MINNEAPOLIS, MN, US, Sept. 02, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Mark Middleton has accepted a position with the Company as its new National Director of Sales.

"With the manufacturing team having successfully implemented commercial manufacture of our initial product, spryng™, our focus on sales has become a key objective to the success of our Company; we believe the vast insight and expertise that Mark possesses puts PetVivo in an excellent position to meet this objective,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Mark is a professional in assembling, coordinating and training a sales force, which can propel the sale of our therapeutic product, spryng with OsteoCushion Technology, for use in companion animals."

Mr. Middleton has more than 38 years of distribution and manufacturing experience in the Animal Health Industry, holding various roles in Sales and Executive Management. As a Division President with Animal Health International (“AHI”), formerly Walco International, he led a team that was instrumental in several company acquisitions, organic growth, and the transition of AHI into a performance-oriented public corporation with revenues of $800 million. In addition to his distribution experience, Mr. Middleton worked as a consultant for FDA manufacturers to develop their markets for both current and new products.

“I am incredibly excited to join PetVivo, a company whose technology has tremendous potential to enhance the lives of companion animals and their owners,” said Mr. Middleton. “I am looking forward to joining a company that possesses disruptive technology, has the ability to grow the market and offers a product that enhances and improves the medical outcomes of animals.”

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216 

Forward-Looking commercial Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.